Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed strong financial performance with a significant increase in revenue and net income, driven by the mRNA platform and cost management. The increase in R&D expenses indicates ongoing investment in clinical trials, suggesting future growth potential. The operational cash flow also improved, supporting financial health. Despite some risks associated with forward-looking statements, the overall financial metrics and strategic investment in R&D provide a positive outlook for the stock price movement over the next two weeks.
Key Financial Performance
Revenue $120 million, a 15% increase year-over-year, driven by strong sales in the mRNA platform.
Net Income $25 million, a 20% increase year-over-year, attributed to cost management and operational efficiencies.
R&D Expenses $45 million, a 10% increase year-over-year, due to expanded clinical trials.
Operating Cash Flow $30 million, a 25% increase year-over-year, supported by improved revenue collection.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are not guarantees of performance and involve risks, uncertainties, and assumptions that could lead to actual results differing materially from expectations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program in the provided text.
Shares Buyback Program: No specific mention of a shares buyback program in the provided text.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adam Walsh
Angela Qian
Arcturus Therapeutics
Blair LLC
Canaccord Genuity
Cantor Fitzgerald
Capital Partners
Co Research
Director Yasmeen
Division Adam
Division Angela
Division Lili
Division PM
Division Pete
Division Yale
EST Shrader
Fitzgerald Co
Hello today
Inc Vice
LLC Research
Laidlaw Hello
Lili Nsongo
Minter Blair
Nsongo Leerink
PM EST
Partners LLC
Pete Stavropoulos
Piper Sandler
Qian Canaccord
ROTH Capital
Research Division
Securities LLC
ARCT Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call revealed strong financial performance with a significant increase in revenue and net income, driven by the mRNA platform and cost management. The increase in R&D expenses indicates ongoing investment in clinical trials, suggesting future growth potential. The operational cash flow also improved, supporting financial health. Despite some risks associated with forward-looking statements, the overall financial metrics and strategic investment in R&D provide a positive outlook for the stock price movement over the next two weeks.
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary and Q&A reveal mixed signals. While there are positive developments in product pipelines and regulatory progress, management's lack of specific guidance on revenue and clinical endpoints creates uncertainty. The Q&A highlighted potential for growth but also pointed to uncertainties in clinical trial outcomes and commercial revenues. No major catalysts like new partnerships or strong financial metrics were announced, leading to a neutral sentiment overall.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript
Unknown8-11
The earnings call presents a mixed picture: strong pipeline developments with FDA fast track designation and cash runway extension are positives, but declining revenue and a net loss are negatives. The Q&A reveals cautious optimism about CF and OTC programs, yet management's lack of clarity on competitor impact and data release timing raises uncertainties. These factors, combined with no new partnerships or shareholder return changes, suggest a neutral stock movement prediction.
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript
Unknown5-12
The earnings call reveals a decline in revenue and increased net loss, alongside an extended cash runway due to cost reductions and facility consolidation. The Q&A session highlights uncertainties, with management avoiding clear answers on key milestones and guidance. Despite a decrease in expenses, the lack of anticipated revenue milestones until 2028 and unclear regulatory feedback contribute to a negative sentiment. While some operational efficiencies were achieved, the overall financial outlook and management's vague responses suggest a negative stock price movement in the short term.
ARCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
